
The company is seeking priority review as it prepares for a potential 2027 launch and reports a third-quarter net loss of $41.9 million.
Kyverna Therapeutics has completed its rolling Biologics License Application submission for miv-cel, a potential treatment for stiff person syndrome, and is seeking priority review from the FDA. The application is based on data from the company’s KYSA-8 trial.
The FDA has not yet approved the treatment. Kyverna said it is preparing for a potential U.S. launch in 2027, including engaging treatment centers and building patient support and reimbursement services.
For the third quarter ended September 30, Kyverna reported a net loss of $41.9 million, or $0.68 per share. Research and development expenses were $27.0 million, while general and administrative expenses were $15.9 million.
The company had $170.6 million in cash, cash equivalents and marketable securities at quarter-end. Together with amounts available under its amended loan facility, Kyverna expects those funds to support operations into 2028.
Kyverna also said enrollment in its Phase 3 trial of miv-cel for generalized myasthenia gravis remains on track to finish in mid-2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.